We are a small group of highly committed and seasoned scientists who have taken the size and severity of this global challenge personally and pledged to commit ourselves to address this before it becomes a bigger global health nightmare.
We are proud of our ongoing commitment to the research and development of new antimicrobial therapies, and we are working hard to ensure that both individual patients and society as a whole will continue to benefit from effective AMR solutions.
The AMR problem and the unmet need
The last novel class of antibacterial agents to be licensed was discovered in 1987. Antimicrobial Resistance (AMR) is one of the major challenges of our time, with devastating and long-lasting consequences. Without effective antimicrobials, common infections can become life-threatening, and even routine treatments such as surgical procedures and chemotherapy would not be possible, making any medical intervention almost impossible.
Stepping up Immunotherapy to the next level Tapping the Tumor Microenvironment
Our research programs focus on discovering affordable, differentiated, small molecule therapeutics for highly hypoxic tumors where adenosine plays a pivotal role in creating an immunosuppressive and tumor-promoting environment.
We believe our deep understanding of medicinal chemistry and Tumor Microenvironment has the potential to help make current immunotherapies more effective by providing the immune system a “kickstart” to initiate and sustain a robust anti-cancer response.
News & Announcements
From Cells to Molecules to Products – an in-depth video on CCAMP done by Pallava Bala for India Science. Bugworks is one of the six companies to be highlighted.
December 15, 2021 Published in Indiascience.com
Bugworks Research Inc. CSO Dr. Santanu Datta underscores need for a Bayh-Dole like Act to propel research commercialization
November 15, 2021 Published in Pharmabiz.com
Bugworks Research starts first human dose study to treat critical bacterial infections – ETHealthWorld
November 10, 2021 Published in ETHealthworld.com
Bugworks Research begins first in human phase 1 study of BWC0977 to treat critical bacterial infections
November 9, 2021 Published in Pharmabiz.com
Our Team
